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ABSTRAK 
 
Latar Belakang 
 
Osteoarthritis lutut adalah penyakit arthritis utama di seluruh dunia yang mempunyai 
kesan ketara ke atas kualiti hidup berkaitan dengan kesihatan. Penggunaan 
perubatan alternatif untuk osteoarthritis semakin popular. Channa striatus, ikan air 
tawar asli di Malaysia adalah terkenal dengan nilai pemakanan dan perubatan dalam 
rawatan tradisional. Bukti-bukti tersedia ada menyokong potensinya dalam rawatan 
pesakit osteoarthritis lutut primer. 
 
Objektif 
 
Tujuan kajian ini adalah untuk membandingkan keberkesanan oral ekstrak Channa 
striatus dan Glucosamine sulphate dalam menambahbaikan gejala lutut dan fungsi 
fizikal, serta dalam penggunaan analgesik penyelamat di kalangan pesakit 
osteoarthritis lutut primer. 
 
Kaedah 
 
Tujuh puluh lapan pesakit dengan osteoarthritis lutut primer telah didaftar ke dalam 
‘double-blind randomized controlled trial’ ini dan diberikan sama ada Channa striatus 
500 mg / hari (n = 39) atau Glucosamine sulphate 1500 mg / hari (n = 39) selama 
enam bulan. Kaedah penentuan keberkesanan adalah Western Ontario dan indeks 
‘Mc Master Osteoarthritis Indeks’ (WOMAC) untuk kesakitan, kekakuan dan fungsi 
fizikal, skala analog visual untuk sakit semasa pergerakan dan skor analgesik untuk 
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kegunaan analgesia penyelamat. Keputusan dari kaedah penentuan keberkesanan 
ini adalah dinilai dengan analisis niat untuk merawat. Semua pesakit telah dinilai 
pada garis permulaan, 3 dan 6 bulan selepas rawatan diberikan. 
  
Keputusan 
 
Semua ciri-ciri asas adalah setanding antara kumpulan Channa striatus dan 
Glucosamine sulphate. Antara 78 pesakit yang menerima rawatan, 73 telah 
menamatkan kajian 6 bulan (Channa striatus , n = 36 dan Glucosamine sulphate , n 
= 37). Tiada perbezaan yang signifikan dari segi statistik antara kedua-dua 
kumpulan dalam indeks WOMAC, skala analog visual dan skor analgesik selepas 
rawatan selama 6 bulan. Walau bagaimanapun, terdapat penambahbaikan yang 
signifikan dari segi statistik dalam semua domain indeks WOMAC berdasarkan 
masa untuk kumpulan Channa striatus dari garis permulaan ke 3 bulan sehingga 6 
bulan. Walaupun terdapat penambahbaikan dari 3 hingga 6 bulan, ianya tidak 
signifikan dari segi statistik. Semua parameter profil keselamatan adalah normal bagi 
kedua-dua kumpulan sebelum dan selepas rawatan. 
 
Kesimpulan 
 
Penggunaan Channa striatus 500 mg / hari adalah setanding dengan Glucosamine 
sulphate 1500 mg / hari dalam menambahbaikan kesakitan, kekakuan dan fungsi 
fizikal pesakit osteoarthritis lutut primer. Ia boleh menjadi rawatan alternatif baru 
dengan profil keselamatan yang baik untuk rawatan jangka panjang osteoarthritis 
lutut.  
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ABSTRACT 
 
Background 
 
Knee osteoarthritis is the commonest form of arthritis worldwide with significant 
impact on the health-related quality of life. Complementary and alternative medicine 
use in osteoarthritis is gaining popularity. Channa striatus, an indigenous fresh water 
fish in Malaysia is well-known for its nutritional and medicinal value in traditional 
medicine. The current evidences support its therapeutic potential in treating primary 
knee osteoarthritis patients.  
 
Objectives 
 
The aim of the study was to compare the effectiveness of oral Channa striatus 
extract and Glucosamine sulphate in improving knee symptoms and physical 
function, as well as in rescue analgesic consumption among primary knee 
osteoarthritis patients. 
 
Methods  
 
Seventy eight patients with primary knee osteoarthritis were enrolled into this double-
blind randomized controlled trial and assigned to receive either Channa striatus 500 
mg/day (n = 39) or Glucosamine sulphate 1500 mg/ day (n = 39) for six months. The 
efficacy outcome measures were Western Ontario and Mc Master Osteoarthritis 
Index WOMAC index for pain, stiffness and physical function, Visual Analogue Scale 
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for pain during movement and Analgesic score for rescue analgesia consumption. 
These outcomes measures were assessed using an intention-to-treat analysis. All 
patients were evaluated at baseline, 3 and 6 months post randomization.   
 
Results 
 
All the baseline characteristics were comparable between Channa striatus and 
Glucosamine sulphate group. Of 78 patients randomized, 73 completed the study 
(Channa striatus, n = 36 and Glucosamine sulphate, n = 37). There were no 
statistically significant difference between these two groups in WOMAC index, Visual 
Analogue scale and Analgesic score after 6 months of intervention. However, there 
were statistically significant improvement in all the domains of WOMAC index based 
on time for Channa striatus group from baseline to 3 months up to 6 months. 
Although there were improvement observed from 3 to 6 months of treatment, they 
were not statistically significant.  All the safety profile parameters were normal for 
both groups before and after the intervention.  
 
Conclusions  
 
Channa striatus 500 mg/ day is comparable to Glucosamine sulphate 1500 mg/ day 
in improving pain, stiffness and physical function in patients with primary knee 
osteoarthritis. It could be a new alternative treatment with good safety profile for 
medium to long term management of knee osteoarthritis. 
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CHAPTER 1 
 
INTRODUCTION 
 
 
1.1 KNEE OSTEOARTHRITIS AND COMPLEMENTARY AND ALTERNATIVE 
MEDICINE  
 
Osteoarthritis is a progressive degenerative joint disease, characterized by articular 
cartilage disruption with new bone formation (1). The knee is the commonest joint 
involved in osteoarthritis (2). The primary knee osteoarthritis implies an idiopathic 
cause or no known prior event or disease leading to osteoarthritis. In order to 
diagnose knee osteoarthritis, there should be knee pain PLUS at least 1 of 3 criteria: 
age > 50 years old, knee stiffness < 30 minutes and/ or crepitus on active movement 
PLUS radiographic osteophytes, as endorsed by American College of Rheumatology 
(ACR) (3).  
 
Knee osteoarthritis is the one of the commonest form of arthritis worldwide. Based 
on the Global Burden of Disease 2010 study, the prevalence of knee osteoarthritis 
was increasing with age with global prevalence of 3.8% in 2010 (4). The Community 
Oriented Program for Control of Rheumatic Disorder (COPCORD) survey for 
musculoskeletal pain in Malaysia had revealed that knee osteoarthritis is the most 
frequently diagnosed condition in knee pain (5). Above all, the burden of 
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osteoarthritis on individual, socioeconomic and health care system is anticipated to 
increase substantially over coming decades with the rising trend of aging population 
worldwide (4).  
 
Various guidelines are developed and constantly updated to effectively manage knee 
osteoarthritis according to evidence-based recommendation. The combination of 
non-pharmacological and pharmacological treatment modalities are crucial for the 
optimal management of knee osteoarthritis. However, the pharmacological treatment 
is mainly as symptom-modifying agents. The first line of symptom-modifying agent 
has been the acetaminophen. Non-steroidal anti-inflammatory agents (NSAIDs) is 
considered in those non-responsive to acetaminophen (6-9). Nevertheless, NSAIDs 
in general were associated with increased risk of serious gastrointestinal, 
cardiovascular and renal harms (10).  
 
Hence, the use of complementary and alternative medicine is gaining popularity 
among individuals with osteoarthritis (11, 12). Those commonly use in osteoarthritis 
include herbals, cod liver oil, vitamins, mineral, glucosamine and chondroitin (12, 
13). Glucosamine is the most persistently used complementary and alternative 
medicine modality among older adults with radiographic knee osteoarthritis (14). 
Studies on Glucosamine sulphate in osteoarthritis have collectively demonstrated a 
superiority to placebo for improvement in pain and physical function (15, 16). 
Moreover, the consumption of rescue pain analgesia (NSAIDs) has significantly 
reduced with continuous use of glucosamine sulphate (17). 
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Apart from glucosamine sulphate, interest has been directed towards the use of 
Channa striatus in treating knee osteoarthritis (18). Channa striatus, an indigenous 
fresh water fish, is well-known as Haruan among Malaysian. It is widely consumed 
as a nutritious food and used as a remedy in traditional medicine. Its therapeutic 
potentials include antimicrobial, antifungal, anti-inflammatory, induction of platelet 
aggregation, promoting cell proliferation as well as anti-nociceptive properties (19).  
 
The evidences on beneficial effects of Channa striatus in treating osteoarthritis had 
been reported in animal studies (20, 21). Thereafter, study conducted on patients 
with knee osteoarthritis had demonstrated a significant improvement in pain, 
symptoms and quality of life following treatment with oral Channa striatus extract for 
3 months (18). Nevertheless, clinical evidence available for effectiveness of Channa 
striatus in treating patient with knee osteoarthritis remained scarce.   
 
Therefore, it would be beneficial to assess the therapeutic effectiveness of Channa 
striatus in knee osteoarthritis over a longer duration of administration, in comparison 
with another well-studied modality of treatment, Glucosamine sulphate.  
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1.2 JUSTIFICATION/ RATIONALE 
 
With the initial evidence of Channa striatus on patient with osteoarthritis, it would be 
beneficial to assess its therapeutic effectiveness over a longer duration of 
administration, in comparison with another well-studied modality of treatment, 
Glucosamine sulphate. The finding from the present study would further consolidate 
the current evidence on Channa striatus in clinical effectiveness and safety over a 
longer term. Moreover, Channa striatus might prove to be a better and yet free of 
side effect complementary alternative medicine than glucosamine sulphate. Above 
all, limit the use of conventional treatment, non-steroidal anti-inflammatory drugs in 
the treatment of knee osteoarthritis.  
 
The cost-effectiveness of treatment and impact on healthcare budget are also 
increasingly important. Channa striatus is an indigenous species in Malaysia. All the 
necessities for farming Channa striatus are well in placed. The Channa striatus 
products farmed and manufactured locally would be cheaper than the imported 
complementary alternative medicine. Thereby mitigate the clinical and 
socioeconomic burden of osteoarthritis in Malaysia. In addition, this would create 
revenue and work opportunities to Malaysians.  
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1.3 OBJECTIVES  
 
General Objectives 
 
To compare the effectiveness of oral Channa striatus (Haruan) extract 500mg/day 
and Glucosamine sulphate 1500mg/day on the symptoms, physical function and 
analgesic consumption among primary knee osteoarthritis patients.  
 
 
Specific Objectives  
 
1. To compare the mean of pain, stiffness, physical function score and global 
score using Western Ontario and Mc Master Osteoarthritis Index (WOMAC) 
between Channa striatus and Glucosamine sulphate group 
 
2. To compare the mean of pain on movement using visual analogue scale 
(VAS) between Channa striatus and Glucosamine sulphate group  
 
3. To compare the mean of analgesic score between Channa striatus and 
Glucosamine sulphate group  
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1.4 RESEARCH HYPOTHESIS  
 
1. There is a significant difference of pain, stiffness, physical function score and 
global score using Western Ontario and Mc Master Osteoarthritis Index 
(WOMAC) between Channa striatus and Glucosamine sulphate group 
 
2. There is a significant difference of pain on movement using visual analogue 
scale (VAS) between Channa striatus and Glucosamine sulphate group  
 
3. There is a significant difference of analgesic score between Channa striatus 
and Glucosamine sulphate group  
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1.5 OPERATIONAL DEFINITION  
 
1. Pain – As measured by pain domain of WOMAC Index and Visual analogue 
scale 
 
2. Joint stiffness – As measured by stiffness domain of WOMAC Index  
 
3. Physical function – As measured by physical function domain of WOMAC 
Index  
 
4. Compliance – More than 80% of medication was consumed as prescribed (4 
capsules per day) within 6 month period  
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CHAPTER 2 
 
LITERATURE REVIEW  
 
 
2.1 Knee Osteoarthritis  
 
Osteoarthritis is a progressive degenerative joint disease. It is characterized by non-
inflammatory disruption of the articular cartilage with reactive new bone formation at 
the joint surface and margins (1). Although defects in the poorly innervated articular 
cartilage are not, in themselves, symptomatic, a clinical syndrome of symptoms, 
often includes pain, may evolve from such defects (3). The process may involve one 
or multiple joints. However, the knee is the commonest site of involvement in 
osteoarthritis (2).  
 
Various classifications exist for subsets of osteoarthritis. It can be classified 
according to site of joint involvement or etiology. The etiological classification 
subdivided the osteoarthritis into primary (idiopathic or no known prior event or 
disease related to osteoarthritis) and secondary (presence of known event or 
disease associated with osteoarthritis) (3).  
 
2.2 Diagnosis of Knee Osteoarthritis  
 
To diagnose primary knee osteoarthritis, three different sets of classification criteria 
could be utilized under different circumstances as endorsed by American College of 
 13 
 
Rheumatology (ACR). These diagnostic criteria sets are grouped under either clinical 
only, clinical and laboratory or clinical and radiographic criteria, with each set yielded 
different diagnostic sensitivity and specificity. For diagnostic criteria set involving 
clinical examination only, there should be knee pain PLUS at least 3 of the following 
6 features: age > 50 years old, knee stiffness < 30 minutes, crepitus on active 
movement, bony tenderness over the knee joint, bony enlargement and no palpable 
warmth. This combination set demonstrated 95% sensitivity and 69% specificity for 
primary knee osteoarthritis (3).  
 
As for the clinical and laboratory criteria set, knee pain PLUS at least 5 of the 
following 9 clinical or laboratory findings should be present (must have at least 1 
laboratory test performed): age > 50 years old, knee stiffness < 30 minutes, crepitus 
on active movement, bony tenderness over the knee joint, bony enlargement, no 
palpable warmth, erythrocyte sedimentation rate (ESR) < 40 mm/ hour, rheumatoid 
factor (RF) < 1:40 and synovial fluid findings suggestive of osteoarthritis (viscous, 
clear, and/or white blood cell count < 2000 cells/mm3). This criteria set is 92% 
sensitive and 75% specific in diagnosing primary knee osteoarthritis (3).  
 
The clinical and radiographic criteria set is the most commonly used diagnostic 
criteria in the clinical trials. This criteria set has the comparable sensitivity of 91% 
and highest specificity of 86% among the three. It consists of knee pain PLUS at 
least 1 of 3 criteria: age > 50 years old, knee stiffness < 30 minutes and/ or crepitus 
on active movement PLUS radiographic osteophytes (3). The radiographic evidence 
of knee osteoarthritis based on Kellgren and Lawrence system has defined the 
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osteoarthritis severity into 5 grades using a combination of osteophyte, degree of 
joint space narrowing, sclerosis and bony deformity as follows (22, 23):  
 
 Grade 0  - No changes 
 Grade 1  - Possible osteophyte and doubtful joint space narrowing  
 Grade 2 - Definite osteophyte and possible joint space narrowing  
 Grade 3 - Moderate multiple osteophytes, definite joint space narrowing,  
                        some sclerosis and possible deformity of bone ends  
 Grade 4 - Large osteophytes, marked joint space narrowing, severe  
  sclerosis and deformity of bone ends  
 
2.3 Prevalence of Knee Osteoarthritis  
 
Knee osteoarthritis is the one of the commonest form of arthritis worldwide. The 
Global Burden of Disease 2010 study had estimated the global prevalence of 
radiographically confirmed symptomatic knee osteoarthritis in 2010 was 3.8%. The 
prevalence was rising with age and peaked at around 50 years old with higher 
percentage in female than in male. In Southeast Asia countries, the prevalence was 
2.2% compared with the highest prevalence of 4.4% in high income Asia Pacific 
countries (4).   
 
The Community Oriented Program for Control of Rheumatic Disorder (COPCORD) 
established in the late 1970s had initiated the effort of assembling data on the 
burden of rheumatic disease in resource constraints developing countries including 
Malaysia. The knee was the commonest site of musculoskeletal pain with knee 
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osteoarthritis being possibly the commonest of all specific rheumatic diseases in 
most of the communities under COPCORD studies. The prevalence of knee 
osteoarthritis had been ranged from 1.4% in urban Filipino to 19.3% in rural 
communities in Iran with the prevalence increases with age (2).  
 
Based on the COPCORD survey for musculoskeletal pain in Malaysia, the 
prevalence of joint and/or musculoskeletal pain was 14.4% in the study population 
with the higher prevalence rate in older age group. The knee pain constituted 64.8% 
of all complaint pertaining to the joints.  More than half of those with knee pain had 
clinical evidence of osteoarthritis making it the most frequently diagnosed condition 
(5).     
 
2.4 Impact of Knee Osteoarthritis  
 
Evidences from various studies either globally or regionally have consistently 
showed that the prevalence of knee osteoarthritis is increasing steeply with age (2, 
4, 5). Although the current level of population aging vary widely by geographical 
region, but all nations are facing with an accelerating numbers of aging population. 
The world’s older population had increased another 10.4 million since 2007 to a total 
of 506 million in 2008 representing a shocking growth of an average of 870,000 
people each month during the year. Many countries in Asia are indeed aging rapidly. 
The population aged 65 years and over in Asia is estimated to increase more than 
double in the next two decades from 6.8% in 2008 to 16.2% in 2040. It is estimated 
that the proportion of people aged 65 years over in Malaysia will increase by 269% 
from 2008 to 2040 (24).  
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With the aging of the world population, the tremendous burden of osteoarthritis on 
individual and socioeconomic (25) is anticipated to pose a major challenge in health 
systems globally. According to the Global Burden of Disease 2010 study on 291 
health conditions, knee and hip osteoarthritis ranked the 11th highest contributor to 
global disability and 38th highest in disability-adjusted life years. The years of life 
lived with disability for hip and knee osteoarthritis had increased to 17.1 million in 
2010 (0.69% of total disability-adjusted life years) compared to 10.5 million in 1990 
(0.42% of total disability-adjusted life years) (4). The major disabilities reported are 
the usual daily activities necessary to maintain independence including inability to 
squat, lifting, climbing, carrying, walking, difficulty in dressing, bathing, combing and 
feeding (5). These pose a significant negative impact on health-related quality of life 
in people with knee osteoarthritis (26).  
 
Moreover, the socioeconomic burden of osteoarthritis has been enormous, typically 
measured in direct and indirect costs. The direct costs are attributed to health care 
provision including non-pharmacological and pharmacological treatment as well as 
long term care (25). Based on a US population-based study of health care utilization 
in individuals with knee osteoarthritis, there was an average of six more physician 
visits and 3.8 more non-physician visits every year than the osteoarthritis-free cohort 
(27). Similarly, the indirect costs incurred are substantial. These are attributed to 
productivity loss from workforce absenteeism, presenteeism (due to effect on 
functional ability) as well as forced early retirement with consequent income loss and 
reduced taxation revenue (28).  
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The burden of osteoarthritis on individual, socioeconomic and health care system is 
anticipated to increase substantially over coming decades particularly in low-income 
and middle-income countries with the rising trend of aging population worldwide. 
Given the magnitude of the disease burden, strategies to reduce knee osteoarthritis 
burden through primary & secondary prevention programs have become increasingly 
important and demanded greater attention (4).  
 
2.5 Management of Knee Osteoarthritis  
 
Various guidelines are developed and constantly updated to effectively manage knee 
osteoarthritis according to evidence-based recommendation. These guidelines 
include European League Against Rheumatism (EULAR) recommendation (2003), 
American College of Rheumatology (ACR) recommendations (2012), Osteoarthritis 
Research Society International (OARSI) guideline (2014) as well as the local 
Malaysia clinical practice guideline (2013). All these guidelines (6-9) in general have 
the recommendation for management of knee osteoarthritis divided into three main 
categories: non-pharmacological, pharmacological and surgical. The combination of 
non-pharmacological and pharmacological treatment modalities are important for 
optimal management of knee osteoarthritis.  
 
The non-pharmacological treatment includes exercise, weight management, strength 
training, self-management, education, physiotherapy and occupational therapy. In 
contrast, the pharmacological treatment is mainly symptom-modifying agents. None 
is  recognized as structure (disease) modifying agent by any guidelines or the 
regulatory agencies (29). The first line of symptom-modifying agent has been 
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acetaminophen with NSAIDS to be considered in those non-responsive to 
acetaminophen (6-8).  
 
 
A meta-analysis of randomized controlled trials assessing the best evidence for 
efficacy of acetaminophen in the treatment of osteoarthritis had confirmed the 
effectiveness of acetaminophen for relieving pain in osteoarthritis. The effect size of 
0.21 was small, but was statistically significant and acetaminophen had a higher 
clinical response rate than placebo (30).  
 
In fact, acetaminophen is well tolerated with good bioavailability after oral 
administration at recommended therapeutic doses (maximum 4 g/ day). No serious 
side effects have been observed although rarer side effects may emerge with higher 
doses or prolonged utilization such as renal dysfunction, higher blood pressure and 
hepatotoxicity. Nevertheless, acetaminophen is safe as a long term treatment up to 6 
– 12 months. The mechanism of action of acetaminophen is complex. Generally, it 
suppresses prostaglandin production but does not possess any anti-inflammatory 
properties (31, 32).    
 
Non-steroidal anti-inflammatory agents (NSAIDs) have better efficacy and higher 
patient preferences compared to acetaminophen in treatment of osteoarthritis (33). 
The effect size of pain relief for NSAIDs was 0.29 (95% CI: 0.22 – 0.35), that was 
greater than acetaminophen with an effect size of 0.14 (95% CI: 0.05 – 0.22) (34). 
Based on a systematic review and network meta-analysis assessing the comparative 
effectiveness of pharmacologic treatment for primary knee osteoarthritis, the 
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ibuprofen, naproxen, diclofenac and celecoxib were significantly superior to 
acetaminophen in pain, stiffness and physical function-related outcomes (35). 
Moreover, Ibuprofen is commonly used in clinical trials of Glucosamine sulphate in 
knee osteoarthritis either for direct comparison (36, 37) or as rescue analgesia 
during the trials (15, 38).      
 
Ibuprofen is a non-steroidal compound with analgesic activity linked to its anti-
inflammatory effects and is related to reduction in cyclo-oxygenase (COX)-1 and 
COX-2 derived prostanoids production (39). It has been used for treatment of 
rheumatic and other more severe musculoskeletal conditions. It has comparable 
therapeutic benefits with coxibs and other NSAIDS (40). In fact, Ibuprofen at a dose 
of 1800 – 2400 mg per day had a good safety profile for treatment of inflammatory 
pain conditions including osteoarthritis, spondylo-arthropathies and other rheumatic 
conditions. The risk for gastrointestinal, hepatorenal and other rarer adverse drug 
reactions is relatively lower compared to other NSAIDS. The pharmacokinetic 
properties of Ibuprofen, particularly the short plasma half-life of elimination and lack 
of pathologically related metabolites production are responsible for its low toxic 
potential (41). 
 
As mentioned, the better efficacy of NSAIDs has to deal with the expense of greater 
side effects. NSAIDs in general were associated with increased risk of serious 
gastrointestinal, cardiovascular and renal harms compared with placebo. Comparing 
both non-selective NSAIDs and selective COX-2 inhibitors, the latter were better or 
comparably tolerated. However, the serious adverse events were similar (10). 
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Hence, cautious use of NSAIDs with conservative dosing and treatment duration is 
mandatory particularly in those with moderate to high co-morbidity risk (7-9).    
 
 
2.6 Complementary Alternative Medicine  
 
In order to prevent and avoid potential adverse effects from conventional 
pharmacological treatment, attention has been directed towards complementary and 
alternative medicine (42, 43). Indeed, the use of complementary and alternative 
medicine is gaining popularity among individuals with osteoarthritis (11, 12). 
According to the World Health Organization, complementary and alternative 
medicine is the knowledge, skills and practices based on the theories, beliefs and 
experiences indigenous to different cultures, whether explicable or not, used in the 
maintenance of health, as well as in the prevention, diagnosis, improvement or 
treatment of physical and mental illnesses (44).  The trend of complementary and 
alternative medicine use is varied between countries around the world (45).  
 
In Malaysia, the complementary and alternative medicine is termed “Traditional and 
complementary medicine”. It comprises a form of health-related practices designed 
to prevent, treat and / or manage illnesses and / or preserve the mental and physical 
well-being of individuals and includes practices such as traditional Malay medicine, 
traditional Chinese medicine, traditional Indian medicine, homeopathy and 
complementary therapies and excludes medical or dental practices utilized by 
registered medical or dental practitioners. Traditional medicine has a remarkable role 
in the present health care system in Malaysia. It has been recognized by Ministry of 
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Health Malaysia as an integral part of national healthcare systems with its own 
National Policy on Traditional and Complementary Medicine established in 1999 
(46).  
 
Based on a study conducted among patients with chronic disease including 
osteoarthritis in Malaysia, the utilization of traditional and complementary medicine 
was common (63.9%) with varying types of modalities reported (42). Majority of the 
elderly in Malaysia perceived traditional and complementary medicine as much more 
effective (55.1%) with minimum side effects (69.5%) compared to the conventional 
medicine (47). Dietary supplements are among the dominant complementary and 
alternative medicine modalities consumed widely (45). Those commonly use in 
osteoarthritis include herbals, cod liver oil, vitamins, mineral, glucosamine and 
chondroitin (12, 13).  
 
2.7 Glucosamine in Knee Osteoarthritis  
 
Glucosamine use is common among individual with knee osteoarthritis. It is the most 
persistently used complementary and alternative medicine modality based on a 4 
years study among older adults with radiographic knee osteoarthritis (14). 
Glucosamine is a natural aminosaccharide forming the constituent of 
glycosaminoglycan in the cartilage matrix and synovial fluid. The potential of 
glucosamine in suppression of numerous inflammatory and degenerative mediators 
have contributed to attenuation of articular cartilage degeneration, thus delaying the 
osteoarthritic disease progression. All these highlighted the role of exogenous 
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glucosamine administration for its symptomatic relief as well as disease-modifying 
effects in osteoarthritis (48, 49).   
 
Numerous studies conducted to determine the effect of glucosamine sulphate on 
osteoarthritis symptoms have collectively demonstrated a superiority to placebo for 
improvement in pain and physical function (15, 16).  The need for rescue pain 
analgesia (NSAIDs) has significantly reduced with continuous use of glucosamine 
sulphate (17). Moreover, there are evidences supporting the disease modifying 
effects of long term glucosamine sulphate. Two studies over 3 years period had 
shown a significant retardation of the joint space narrowing in osteoarthritis (50, 51). 
Above all, treatment with glucosamine sulphate for at least 12 months and up to 3 
years may delay the need for total joint replacement for at least 5 years following 
treatment discontinuation (52). Long term treatment with glucosamine sulphate is 
also well-tolerated and safe with a comparable adverse event rate to placebo. In fact, 
the adverse events (i.e. headache, abdominal pain, dyspepsia, diarrhea) reported 
were generally transient and of mild to moderate severity (51, 53, 54).  
 
Consequently, the European Society for Clinical and Economic Aspects of 
Osteoporosis and Osteoarthritis (ESCEO) algorithm for management of knee 
osteoarthritis has made recommendation for chronic use of symptomatic slow-acting 
drugs for osteoarthritis, in particular prescription glucosamine sulphate and 
chondroitin sulphate, as the first line pharmacological treatment for slow onset 
medium to long term control of symptoms (55). In addition, the guidelines from 
European League Against Rheumatism (EULAR) has graded both glucosamine 
sulphate and chondroitin sulphate with high level of evidence for symptomatic 
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treatment of osteoarthritis (6). Based on Malaysia clinical practice guideline, 
glucosamine sulphate is also recommended as part of treatment consideration at 
any time in managing osteoarthritis (8).  
 
 
2.8 Channa striatus in Knee Osteoarthritis  
 
In Malaysia, there are various types of complementary and alternative medicine use 
for treatment of chronic diseases including osteoarthritis (42). Apart from 
glucosamine sulphate, interest has been growing towards the use of Channa striatus 
as a local traditional remedy in treating knee osteoarthritis (18). Channa striatus is 
well-known as Haruan among Malaysian. It is an indigenous fresh water fish species 
belonging to the family of Channidae and widely distributed in several Asian 
countries including Malaysia. Other than consumed as a nutritious food, it is also 
popular as a remedy in traditional medicine, especially in post-operative wound 
healing (19).  
 
Studies had been done on different components of Channa striatus including the 
fillets, roe (gonad of the fish in the pre-spawning season) and the mucous covering 
of the fish to analyze its biochemical compositions. It has a very good composition of 
amino acids and fatty acids as well as mineral compounds that contributed to its 
highly valued medicinal properties (56, 57). The important amino acids are glycine, 
lysine and arginine, whereas the fatty acids are arachidonic acid, palmitic acid and 
docosahexaenoic acid (38). The therapeutic potential of Channa striatus including 
 24 
 
antimicrobial, antifungal, anti-inflammatory, induction of platelet aggregation, 
promoting cell proliferation as well as anti-nociceptive properties (19).  
 
The wound healing properties of Channa striatus was explored by Baie et al. in a 
study that focused on the effects of Channa striatus on different constituents of 
extracellular matrix of healing wounds in rats. The Channa striatus treated wounds 
had an increase in uronic acid content suggesting an enhanced glycosaminoglycan 
synthesis in the healing wounds (58). The glycosaminoglycan has been an important 
first component of extracellular matrix synthesized during wound healing process 
(59). In addition, there was an increased hyaluronic acid, dermatan, keratin and 
chondroitin sulphate in the Channa striatus treated wounds that all together 
increased the rate of wound contraction and formed a stable scar, accelerating the 
process of wound healing (58).  
 
The effectiveness of Channa striatus in wound healing was further substantiated by 
the observation of its ability to increase the tensile strength of the wounds. It 
promotes the collagen remodeling through synthesis of inter-and intra-molecular 
protein that cross-linked to form fibrous scar, the end process of wound healing (60). 
On these basis, Channa striatus is gaining its role in wound healing with more 
convincing scientific explanation for its potential therapeutic effects.   
 
Apart from wound healing properties, the anti-nociceptive effect of Channa striatus is 
another interesting focus in the research. The anti-nociceptive activity of whole fillet 
and mucous extracts of Channa striatus was first studied on mouse by Mat Jais et al. 
in 1977 to establish the scientific basis for the well-known pain-relieving effects of the 
